To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:2 Issue:7 Number:167 ISSN#:2564-2537
DOWNLOAD ESPAÑOL
RCT
ACE Report #754
Ace Report Cover Metabolic Disorders

Teriparatide increases BMD in patients with glucocorticoid-Induced osteoporosis


How to Cite

OrthoEvidence. Teriparatide increases BMD in patients with glucocorticoid-Induced osteoporosis. ACE Report. 2013;2(7):167. Available from: https://myorthoevidence.com/AceReport/Report/754

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis

N Engl J Med. 2007 Nov 15;357(20):2028-39

Contributing Authors:
KG Saag E Shane S Boonen F Marín DW Donley KA Taylor GP Dalsky R Marcus

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

428 patients with glucocorticoid-induced osteoporosis were randomised to receive one of two treatments. The first group received a treatment of 20 μg teriparatide daily while the second group received a 10 mg alendronate treatment. The primary outcome was change in bone mineral density at the lumbar spine from baseline to the 18-month follow-up. Results indicated that bone mineral density increas...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.